Our Services

Are you a small or medium-sized biotech company with promising drug candidates?

Our Services will maximise your potential by making informed decisions about your assets.

BUSINESS DEVELOPMENT

  • We assist in navigating the complex landscape of funding options, including venture capital, private equity, grants, and public offerings. We leverage our extensive network to connect you with relevant investors and facilitate introductions.

  • We meticulously research and evaluate potential partners, including pharmaceutical companies, biotech firms, research institutions, and CROs, based on strategic fit, complementary capabilities, and shared objectives. We guide you through the negotiation process, ensuring that partnership agreements are aligned with your strategic goals and maximise value for your company.

  • We conduct in-depth market research to identify unmet medical needs, assess market size and growth potential, and analyse competitive landscapes. We assist in defining your target patient populations, considering factors such as demographics, disease prevalence, and treatment patterns. We provide ongoing competitive intelligence to stay abreast of market trends, competitor activities, and emerging technologies.

  • We actively scout for promising technologies, intellectual property, and early-stage assets that align with your strategic objectives and enhance your product pipeline. We guide you through the negotiation and structuring of in-licensing agreements, ensuring favourable terms and conditions that protect your interests.

PARTNERING

  • We leverage our extensive network and deep industry knowledge to identify and connect you with the most relevant companies and investors at key industry conferences and partnering events. We facilitate strategic introductions with potential partners, investors, and collaborators, maximising your visibility and increasing the likelihood of successful partnerships. We develop customised strategies for each event, including identifying key objectives, prioritising target companies, and optimising your meeting schedules to maximise your time and resources.

  • We assist in identifying and evaluating potential licensees, negotiating favourable terms and conditions, and structuring licensing agreements that maximise upfront payments, milestone payments, and royalty rates. We ensure that licensing agreements adequately protect your intellectual property rights while facilitating successful technology transfer.

  • We assist in developing and implementing M&A strategies, including identifying potential acquisition targets, evaluating strategic fit, and conducting financial and operational due diligence. We provide guidance and support throughout the entire M&A process, from deal initiation and negotiation to closing and integration. We conduct rigorous financial modelling and valuation analyses to support informed decision-making and maximise shareholder value.

  • We conduct in-depth due diligence on potential partners, acquisition targets, and in-licensing opportunities, covering scientific, technical, commercial, financial, and legal aspects. We identify and assess potential risks and develop strategies to mitigate those risks. We provide clear and concise reports and presentations summarising our findings and recommendations, enabling you to make informed decisions with confidence.

COMMERCIALISATION

  • We develop comprehensive and robust commercialisation strategies that address all key aspects of bringing your product to market successfully. This includes:

    Market Access Strategy: Developing strategies for pricing, reimbursement, and market access to ensure patient access and sustainable revenue generation.

    Go-to-Market Strategy: Defining optimal launch strategies, including sales and marketing plans, distribution channels, and key opinion leader engagement programs.

    Competitive Intelligence: Analysing competitive landscapes and developing strategies to differentiate your product and achieve market leadership.

  • We conduct in-depth portfolio analyses to prioritise development programs based on factors such as scientific validity, market potential, competitive landscape, and resource allocation. We identify and assess key risks associated with each program, including clinical, regulatory, and commercial risks, and develop strategies to mitigate those risks. We help you optimise resource allocation across your portfolio to maximise the return on investment and accelerate the development of your most promising programs.

  • We develop comprehensive and sophisticated risk-adjusted NPV models that accurately reflect the uncertainties and complexities inherent in drug development. We provide clear and actionable insights from our NPV analyses to support critical business decisions, such as licensing negotiations, investment decisions, and portfolio prioritisation.

VALUATION APPROACH

Recognising that groundbreaking science alone is not enough, I have cultivated a deep understanding of the business principles necessary to translate scientific discoveries into successful commercial ventures. I embrace the challenge of bridging the gap between the laboratory and the marketplace. Risk-adjusted Net Present Value (rNPV) is the gold standard valuation method for biopharma assets.

Find out more